Solid-state stability study of meropenem - solutions based on spectrophotometric analysis

Chemistry Central Journal

Volumn 7, Issue 1, 2013, Pages

  Cielecka Piontek, Judyta ^a   Paczkowska, Magdalena ^a   Lewandowska, Kornelia ^b   Barszcz, Boleslaw ^b   Zalewski, Przemyslaw ^a   Garbacki, Piotr ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^b INSTITUTE OF MOLECULAR PHYSICS   (Poland)

Author keywords

Degradation; Derivative spectroscopy; FT IR spectroscopy; Meropenem; Raman spectroscopy; Solid state

Indexed keywords

EID: 84878634916     PISSN: None     EISSN: 1752153X     Source Type: Journal    
DOI: 10.1186/1752-153X-7-98     Document Type: Article

References (28)

1. Nicolau DP. Carbapenems: a potent class of antibiotics. Expert Opin Pharmacother 2008, 9:23-37. 10.1517/14656566.9.1.23, 18076336.
2. Hurt M, Lamb H. Meropenem: a review of its use in patients in intensive care. Drugs 2000, 59:653-680. 10.2165/00003495-200059030-00016, 10776838.
3. Zhanel G, Wiebe R, Dialy L, Thomsaon K, Rubistein E, Hoban D, Noreddin A, Karlowsky J. Comparative review of the carbapenems. Drugs 2007, 67:1027-1052. 10.2165/00003495-200767070-00006, 17488146.
4. Edwards SJ, Emmas CE, Campbell HE. Systematic review comparing meropenem with imipenem pluscilastatin in the treatment of severe infections. Current Medical Research and Opinion 2005, 21:785-794. 10.1185/030079905X46223, 15969878.
5. Deshpande AD, Baheti KG, Chatterjee NR. Degradation of β-lactam antibiotics. Curr Scien 2004, 12:1684-1695.
6. Sajonz P, Wu Y, Natishan TK, McGachy NT, Tora DD. Challenges in the analytical method development and validation for an unstable active pharmaceutical ingredient. J Chrom Scien 2006, 44:132-140.
7. Markovic BD, Dobricic VD, Vladimirov SM, Cudina OS, Savic VM, Karlikkovic-Rajic KD. Investigation of solvolysis kinetics of New synthesized fluocinolone acetonide C-21 esters-an In vitro model for prodrug activation. Molecules 2011, 16:2658-2671. 10.3390/molecules16032658, 21441868.
8. Llinas A, Page MI. Intramolecular general acid catalysis in the aminolysis of beta-lactam antibiotics. Org Biomol Chem 2004, 5:651-654.
9. Cielecka-Piontek J, Michalska K, Zalewski P, Jelińska A. Recent advances in stability studies of carbapenems. Cur Pharm Anal 2011, 7:213-227.
10. Kataoka H. New trends in samples preparation for clinical and pharmaceutical analysis. Tr Anal Chem 2003, 22:232-244.
11. Görög S. The changing face of pharmaceutical analysis. Tr Anal Chem 2007, 27:12-17.
12. Papp-Wallace KM, Endimiani A, Taracila MA, Bonomo RA. Carbapenems: past, present and future. Antimicrob Agents Chemother 2011, 55:4943. 10.1128/AAC.00296-11, 3195018, 21859938.
13. Mohr JF. Update on the efficacy and tolerability of meropenem in the treatment of serious bacterial infections. Clin Infect Dis 2008, 47:S41-S51. 10.1086/590065, 18713049.
14. Jones RN, Sader HS, Fritsche TR. Comparative activity of doripenem and three other carbapenems tested against Gram-negative bacilli with various β-lactamase resistance mechanisms. Diagn Microbiol Infect Dis 2005, 52:71-74. 10.1016/j.diagmicrobio.2004.12.008, 15878447.
15. Rhomberg PR, Jones RN. Contemporary activity of meropenem and comparator broad-spectrum agents: MYSTIC program report from the United States component (2005). Diagn Microbiol Infect Dis 2007, 57:207-215. 10.1016/j.diagmicrobio.2006.07.009, 16949243.
16. Payen MC, Wit D, Martin C, Sergysels R, Muylle I, Laethem Y, Clumeck N. Clinical use of the meropenem-clavulanate combination for extensively drug-resistant tuberculosis. Inter J Tuber Lung Dis 2012, 16:558-560.
17. Hugonnet JE, Tremblay LW, Boshoff HI, Barry CL, Blanchard JS. Meropenem-clavulanate is effective against extensively drug-resistant mycobacterium tuberculosis. Science 2009, 27:1215-1218.
18. Cielecka-Piontek J, Zaja{ogonek}c M, Jelińska A. A comparison of the stability of ertapenem and meropenem in pharmaceutical preparations in solid state. J Phamraceutical Biomedical Analysis 2008, 46:52-57.
19. Mendez A, Chagastelles P, Palma E, Nardi N, Schapoval E. Thermal and alkaline stability of meropenem: degradation products and cytotoxicity. Int J Pharm 2008, 350:95-102. 10.1016/j.ijpharm.2007.08.023, 17904314.
20. Elragehy NA, Abdel-Moety EM, Hassan NY, Rezk MR. Stability-indicating determination of meropenem in presence of its degradation product. Talanta 2008, 77:28-32. 10.1016/j.talanta.2008.06.045, 18804594.
21. Cielecka-Piontek J, Jelińska A, Dołhań A, Zalewski P. Kinetic and thermodynamic analysis of degradation of doripenem in solid state. Inter J Chem Kinet 2012, 44:722-728.
22. Sajonz P, Vailayay A, Sudah O, McPherson L, Capodanno V, Natishan TK, Helmy R, Antia FD. Development of a gradient eluation preparative high performance liquid chromatography method for the recovery of the antibiotics ertapenem from crystallization process streams. J Chrom A 2008, 8:365-372.
23. Berthoin K, Le Duff C, Marchand-Brynaert J, Carryn S, Tulkens P. Stability of meropenem and doripenem solutions for administration by continuous infusion. J Antimicrob Chemother 2010, 65:1073-1075. 10.1093/jac/dkq044, 20176578.
24. Cielecka-Piontek J, Michalska K, Zalewski P, Zasada S. Comparative review of analytical techniques for determination of carbapenems. Cur Anal Chem 2012, 8:91-115.
25. Cielecka-Piontek J, Jelińska A. The UV-derivative spectrophotometry for the determination of doripenem in the presence of its degradation products. Acta Spectrochim A 2010, 77:554-557.
26. Cielecka-Piontek J, Lunzer A, Jelińska A. Stability-indicating derivative spectrophotometry method for the determination of biapenem in the presence of its degradation products. Cent Eur J Chem 2011, 9:35-40.
27. Validation of analytical procedures, Proceeding of the International Conference of Harmonisation (ICH), Commission of the European Communities 1996, Geneva, Switzerland, .
28. Frisch MJ, Trucks GW, Schlegel HB, Scuseria GE, Robb MA, Cheeseman JR, Montgomery JA, Vreven T, Kudin KN, Burant JC, Millam JM, Iyengar SS, Tomasi J, Barone V, Mennucci B, Cossi M, Scalmani G, Rega N, Petersson GA, Nakatsuji H, Hada M, Ehara M, Toyota K, Fukuda R, Hasegawa J, Ishida M, Nakajima T, Honda Y, Kitao O, Nakai H, et al. Gaussian 03, Revision B.05 2003, Pittsburgh PA: Gaussian, Inc.